The absence of a formal nomination has sustained the leading market outcome for no announcement by year-end, reflecting an extended White House review process after Marty Makary’s May 2026 resignation. Acting Commissioner Kyle Diamantas holds strong positioning due to his current role leading the Human Foods Program and reported staff confidence, yet recent shortlists have elevated other contenders including White House adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon official Stephen Ferrara. Brett Giroir and Stephen Hahn draw support from prior Trump administration experience in health roles. Trader pricing remains closely contested because Senate confirmation dynamics, shifting administration priorities, and additional vetting outcomes could rapidly consolidate or fragment support ahead of any announcement.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডNo announcement by December 31 19.0%
Kyle Diamantas 13%
Brett Giroir 10.7%
Sara Brenner 7.2%
$18,953 Vol.
$18,953 Vol.
Dec 31, 2026
Kyle Diamantas
23%
Stephen Hahn
6%
Brett Giroir
11%
Grace Graham
4%
Sara Brenner
7%
No announcement by December 31
28%
No announcement by December 31 19.0%
Kyle Diamantas 13%
Brett Giroir 10.7%
Sara Brenner 7.2%
$18,953 Vol.
$18,953 Vol.
Dec 31, 2026
Kyle Diamantas
$6,163 Vol.
23%
Stephen Hahn
$1,802 Vol.
6%
Brett Giroir
$3,007 Vol.
11%
Grace Graham
$4,151 Vol.
4%
Sara Brenner
$2,798 Vol.
7%
No announcement by December 31
$1,032 Vol.
28%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The absence of a formal nomination has sustained the leading market outcome for no announcement by year-end, reflecting an extended White House review process after Marty Makary’s May 2026 resignation. Acting Commissioner Kyle Diamantas holds strong positioning due to his current role leading the Human Foods Program and reported staff confidence, yet recent shortlists have elevated other contenders including White House adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon official Stephen Ferrara. Brett Giroir and Stephen Hahn draw support from prior Trump administration experience in health roles. Trader pricing remains closely contested because Senate confirmation dynamics, shifting administration priorities, and additional vetting outcomes could rapidly consolidate or fragment support ahead of any announcement.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 12, 2026, 7:59 PM ET
ভলিউম
$18,953শেষ তারিখ
Dec 31, 2026মার্কেট ওপেন হয়েছে
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The absence of a formal nomination has sustained the leading market outcome for no announcement by year-end, reflecting an extended White House review process after Marty Makary’s May 2026 resignation. Acting Commissioner Kyle Diamantas holds strong positioning due to his current role leading the Human Foods Program and reported staff confidence, yet recent shortlists have elevated other contenders including White House adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon official Stephen Ferrara. Brett Giroir and Stephen Hahn draw support from prior Trump administration experience in health roles. Trader pricing remains closely contested because Senate confirmation dynamics, shifting administration priorities, and additional vetting outcomes could rapidly consolidate or fragment support ahead of any announcement.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
ভলিউম
$18,953শেষ তারিখ
Dec 31, 2026মার্কেট ওপেন হয়েছে
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...The absence of a formal nomination has sustained the leading market outcome for no announcement by year-end, reflecting an extended White House review process after Marty Makary’s May 2026 resignation. Acting Commissioner Kyle Diamantas holds strong positioning due to his current role leading the Human Foods Program and reported staff confidence, yet recent shortlists have elevated other contenders including White House adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon official Stephen Ferrara. Brett Giroir and Stephen Hahn draw support from prior Trump administration experience in health roles. Trader pricing remains closely contested because Senate confirmation dynamics, shifting administration priorities, and additional vetting outcomes could rapidly consolidate or fragment support ahead of any announcement.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা